Xie C, Yuan X, Chen SH, Liu ZY, Lu DL, Xu F, Chen ZQ, Zhong XM. Successful response to camrelizumab in metastatic bladder cancer: A case report. World J Clin Cases 2022; 10(1): 254-259 [PMID: 35071525 DOI: 10.12998/wjcc.v10.i1.254]
Corresponding Author of This Article
Xiao-Ming Zhong, PhD, Chief Doctor, Department of Radiotherapy, Jiangxi Provincial Tumour Hospital, No. 519 Beijing East Road, Nanchang 330029, Jiangxi Province, China. jddxf2012@126.com
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Chen Xie, Xia Yuan, Shu-Hui Chen, Zhi-Yong Liu, Di-La Lu, Xiao-Ming Zhong, Department of Radiotherapy, Jiangxi Provincial Tumour Hospital, Nanchang 330029, Jiangxi Province, China
Chen Xie, Xia Yuan, Shu-Hui Chen, Zhi-Yong Liu, Di-La Lu, Xiao-Ming Zhong, Department of Radiotherapy , The Affiliated Cancer Hospital of Nanchang University, Nanchang 330029, Jiangxi Province, China
Feng Xu, Zhi-Qiu Chen, Faculty of Medicine, Burning Rock Biotech, Guangzhou 510300, Guangdong Province, China
Author contributions: Zhong XM and Xie C conceived and designed the case report; Yuan X collected the data; Liu ZY, Chen SH, Xie C, and Chen ZQ performed the analysis; Lu DL performed the follow-up and recorded treatment-related side effects; Xu F and Zhong XM wrote the paper.
Informed consent statement: Informed written consent was obtained from the patient for the publication of this case report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Ming Zhong, PhD, Chief Doctor, Department of Radiotherapy, Jiangxi Provincial Tumour Hospital, No. 519 Beijing East Road, Nanchang 330029, Jiangxi Province, China. jddxf2012@126.com
Received: March 11, 2021 Peer-review started: March 11, 2021 First decision: May 11, 2021 Revised: May 20, 2021 Accepted: July 12, 2021 Article in press: July 12, 2021 Published online: January 7, 2022
Abstract
BACKGROUND
There has been no report to use camrelizumab with chemotherapy for advanced bladder cancer patients with positive programmed death-ligand 1 (PD-L1) expression and high tumor mutational burden (TMB). More effective predictors of bladder cancer immunotherapy have yet to be explored, and the combination of multiple factors may be more predictive than a single factor.
CASE SUMMARY
We report the case of a 74-year-old male patient with recurrent metastatic bladder cancer, which demonstrated positive PD-L1 expression and high TMB. The immune checkpoint inhibitor camrelizumab was administered to the patient in combination with gemcitabine and cisplatin. The patient achieved a partial response with a progression-free survival of 11 mo.
CONCLUSION
This is the first report to use camrelizumab with chemotherapy for advanced bladder cancer patients with positive PD-L1 expression and high TMB.
Core Tip: Eighty percent of patients with positive programmed death-ligand 1 (PD-L1) expression are unable to benefit from immunotherapy. Herein, we report the case of a 74-year-old male patient with recurrent metastatic bladder cancer, which demonstrated positive PD-L1 expression and high tumor mutational burden. The immune checkpoint inhibitor camrelizumab was administered to the patient in combination with gemcitabine and cisplatin. The patient achieved a partial response with a progression-free survival of 11 mo. More effective predictors of bladder cancer immunotherapy have yet to be explored, and the combination of multiple factors may be more predictive than a single factor.
